AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Stenting Versus Neurosurgical Treatment of Idiopathic Intracranial Hypertension.

RecruitingNAAges 18 Years - anyAllFondation Ophtalmologique Adolphe de Rothschild
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Idiopathic intracranial hypertension (HTICi) is a pathology, affecting young adults with a predominance of women, due to an increase in intracranial pressure, which may be associated with stenosis of the cerebral venous sinuses and whose origin remains unknown. This hypertension can lead to papillary edema (OP) which can lead to a narrowing of the visual field and progress to blindness. Along with weight reduction, acetazolamide, which reduces the production of cerebrospinal fluid (CSF), is prescribed as a first-line treatment. Its efficacy is inconsistent in resolving papillary edema and there are many side effects. In the event of ineffectiveness or dependence on acetazolamide associated with hygiene and dietetic rules, a second line of therapy is then considered: neurosurgical (internal shunt of the LCS) or endovascular (venous stenting) treatment. These invasive techniques have ea

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Patient aged 18 or over * HTICi proven greater than 25cm of water * Presence of papillary edema (grade\> 0 on the Frisen scale) * Stenosis of at least one transverse sinus on MRI * Failure of medical treatment and surgical / interventional indication defined by the medical team taking care of the patient * Consent to participate in the study Exclusion Criteria: * Fulminant HTICi * Contraindication to antiplatelet aggregation * Contraindication to one or the other of the interventions under study * Pregnant or breastfeeding woman
๐Ÿ’Š

What it tests

  • venous sinus stenting
  • Neurosurgical internal ventricular shunt
๐Ÿ“

Where

1 site
Fondation A De Rothschild
Paris, France
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy